Peptide vial labels, open date and how long a vial lasts
A peptide vial is a sealed glass container closed by an elastomeric stopper under a crimped metal cap, usually holding a freeze-dried solid. Its label carries identity, strength, storage condition, expiry and whether the container is single-dose or multiple-dose. That classification, rather than the volume inside, governs how long the container may be used once the closure is punctured.
What a vial is, in packaging terms
The words on a carton are not decoration. FDA's 2018 guidance on package type terms defines three categories, and each carries a different expectation about preservatives and about the time the container stays in use.
| Package type term | Definition | Antimicrobial preservative | Convention after first entry |
|---|---|---|---|
| Single-dose container | Sterile medication for parenteral administration, not required to meet antimicrobial effectiveness testing; designed for a single patient as a single injection or infusion. Vials, ampoules and prefilled syringes are examples | Not required | USP 797, Section 15.1: entered only in ISO Class 5 or cleaner air and used up to 12 hours after initial puncture; an opened ampoule is not stored at all |
| Multiple-dose container | Sterile medication that has met antimicrobial effectiveness testing or is excluded from it; intended to contain more than one dose, and generally expected to hold 30 mL or less. A vial is the stated example | Antimicrobial effectiveness testing met, or the product excluded from it | USP 797, Section 15.2: not used for more than 28 days from first entry unless the manufacturer specifies otherwise on the labelling |
| Single-patient-use container | Sterile medication intended to be used multiple times for a single patient; patient-controlled analgesia cartridges and certain injection pens are the examples given | Varies | Per the manufacturer's labelling |
The 28-day figure is a convention drawn from compounding and infection-control practice, not a property of any substance. It appears in USP General Chapter 797, in the FDA guidance above and in CDC's injection safety guidance, always in the same shape: a preserved multiple-dose container is dated when first punctured and discarded 28 days later unless its own labelling says something different, and never past the manufacturer's expiry date.
Lyophilized peptides: what freeze-drying is and why the powder looks the way it does
Lyophilisation, or freeze-drying, is described by FDA's inspection guide as three separate, unique and interdependent processes: freezing, primary drying (sublimation) and secondary drying (desorption).
In the first stage the filled solution is frozen well below its eutectic point, so that the water forms ice crystals and everything dissolved is pushed into the spaces between them. In the second stage the chamber pressure is lowered below the vapour pressure of that ice, and the ice passes directly from solid to vapour without ever becoming liquid. What is left behind is a porous skeleton that occupies the same volume the frozen solution did, which is why a cake can look substantial while weighing a few milligrams. In the third stage the temperature is raised and the water still bound to the solid is driven off by desorption. The review literature on solid protein and peptide pharmaceuticals (Wang 2000; Manning et al. 2010) describes freeze-dried formulations as typically specified below roughly 1 percent residual moisture by weight, determined by Karl Fischer titration.
Two consequences follow, and between them they explain most of what is visible in the container.
Bulking agents shape the cake. A few milligrams of peptide cannot form a structure on its own. Formulations therefore commonly include a bulking agent such as mannitol, together with stabilisers, which is what gives the cake its body and its characteristic white opacity. The same review literature treats excipient choice as the main determinant of both cake structure and storage stability.
The container is closed inside the dryer. Freeze-drying closures are slotted so that water vapour can leave the container while it sits in the chamber, and they are pressed home at the end of the cycle, under vacuum or an inert gas, before the batch is capped. The solid inside was therefore never exposed to room air, and the closure system that achieved that is treated as part of the product rather than as packaging around it.
What happens to that solid afterwards is a storage question rather than a manufacturing one: residual moisture and the glass transition temperature it depresses, condensation on cold glass, and the temperature class a label states are covered in the storage guide and, for the warm end of the range, in peptides at room temperature.
What the powder is allowed to look like
Freeze-dried solid is notoriously variable in appearance, and the pharmaceutical literature treats that variability as expected rather than alarming. A 2017 review in the Journal of Pharmaceutical Sciences set out a harmonised vocabulary for cake appearance precisely because, for product released under a validated drying cycle, non-ideal appearance is often an inherent characteristic of the formulation, the fill volume and the drying cycle rather than a defect.
| What is seen | Mechanism | What it says about content, for material released under a validated drying cycle |
|---|---|---|
| Intact porous cake filling the base | The solid retained the shape of the frozen matrix through sublimation | Nothing beyond a well-behaved cycle |
| Thin film or glaze on the glass | Very low solid load, or the solution wetted the wall before freezing | Nothing about quantity |
| Loose crumbs, or a cake broken into pieces | Mechanical shock in transit; a dried cake is brittle | Nothing about quantity |
| Cake detached and lying tilted or shifted | The cake shrank away from the wall during drying and moved later | Nothing about quantity |
| Vial that looks empty | A few milligrams of light, porous solid across a wide base | Nothing about quantity |
| Shrunken, glassy or collapsed cake | Collapse or meltback, two drying-cycle defects described in FDA's lyophilization inspection guide | A process observation, judged by the manufacturer against the batch record rather than by the eye |
| Visible moisture, or discolouration | Change since the container was sealed, rather than an outcome of the drying cycle | Nothing about the cycle; what such a change indicates is a storage question |
Every row above describes material released under a validated drying cycle, and appearance is judged against the manufacturer's own handling guidance for the specific product rather than by eye. The distinction that matters is between shape and chemistry. Shape, in this list, is almost always uninformative: appearance is not a quantity measurement, and no visual inspection of a closed container establishes how much solid it holds. The last row is the exception, because moisture and colour point to change after sealing rather than to anything the drying cycle did; what such a change indicates, and why an unchanged appearance establishes nothing in the other direction, is set out in how to store peptides. In pharmacy practice a container showing either is treated as compromised and is not returned to use; that judgement follows the labelling of the specific product and belongs with a pharmacist.
The parts of a vial and what each one does
Every element of the container has its own standard, and the standards are a good description of what each part is for.
| Part | Standard | Function |
|---|---|---|
| Glass body | ISO 8362-1 (vials made of glass tubing); glass classified by USP General Chapter 660 | Holds the content. Type I is borosilicate glass, with high hydrolytic and thermal shock resistance; Type II is surface-treated soda-lime glass; Type III is untreated soda-lime glass with moderate hydrolytic resistance |
| Elastomeric closure (stopper) | ISO 8362-2; freeze-drying closures are covered separately by ISO 8362-5 | Reseals after a needle is withdrawn. The standard states these closures are intended for single use only. Freeze-drying variants are slotted so water vapour can escape while the container sits in the dryer, and are pressed home inside the chamber at the end of the cycle |
| Aluminium crimp cap | ISO 8362-3 | Holds the closure against the flange under permanent compression, which is what maintains the seal |
| Flip-off disc on the cap | ISO 8362-6 and ISO 8362-7 (aluminium-plastics combination caps) | A tamper-evident cover over the centre of the closure. Lifting it exposes the septum; the crimp ring underneath stays in place, because it is the ring, not the disc, that keeps the container closed |
Two points follow from that table. The septum, once the flip-off disc has been lifted, is the single place where the sterile inside meets the outside world, and it is the only route to the contents, since the crimp ring that actually holds the closure is not removed. And that septum is treated accordingly: in compounding practice, USP General Chapter 797, Section 8.3 lists vial stoppers as critical sites that are wiped with sterile 70% isopropyl alcohol and allowed to dry before entry.
Vial sizes and the R designation
Tubing vials are designated by an R series, and the number is not the volume of liquid a container is filled with. It is a size class; the standard specifies the overflow capacity, which is the brim-full volume, along with the outer dimensions.
| Size designation (ISO 8362-1) | Overflow capacity | Outer diameter | Height |
|---|---|---|---|
| 2R | 4 mL | 16 mm | 35 mm |
| 4R | 6 mL | 16 mm | 45 mm |
| 6R | 10 mL | 22 mm | 40 mm |
| 8R | 11.5 mL | 22 mm | 45 mm |
| 10R | 13.5 mL | 24 mm | 45 mm |
| 15R | 19 mL | 24 mm | 60 mm |
| 20R | 26 mL | 30 mm | 55 mm |
| 25R | 32.5 mL | 30 mm | 65 mm |
| 30R | 37.5 mL | 30 mm | 75 mm |
The gap between overflow capacity and the volume actually inside is deliberate. Headspace is needed for the freeze-drying cycle, for the closure, and for the pressure changes that come with adding or withdrawing liquid. It also explains why a container filled to its labelled amount can still look mostly empty: overflow capacity and fill volume are different numbers. Diameter and height vary independently across the series, so a larger size class is not automatically a taller container: the 6R body holds more than the 4R body while standing 5 mm shorter, because it is 6 mm wider.
Reading a peptide vial label
| Element | What it records | Where the convention comes from |
|---|---|---|
| Identity and strength | What the container holds and how much, in mg | Pharmacopoeial labelling practice |
| Lot or batch number | The production run, which is the unit of traceability if anything is later questioned | Manufacturing and recall practice |
| Manufacturing or fill date | The point from which the stability period supported by the data is counted | Manufacturing and pharmacopoeial labelling practice |
| Expiry date | The end of the period supported by stability data, for the unopened container under the labelled storage condition | USP General Chapter 659, expiration date and beyond-use date |
| Storage statement | The temperature class the stability data assumes, expressed in the classes defined in USP General Chapter 659 | USP General Chapter 659 |
| Package type statement | Whether the container is single-dose or multiple-dose, which sets the convention after first entry | FDA package type terms guidance, 2018 |
| Discard statement | When to stop using an entered container | FDA package type terms guidance, 2018 |
One phrase deserves separate treatment, because it is widely misread. "For research use only" is a labelling statement, not a legal category. FDA's guidance on research-use and investigational-use labelling makes the general principle explicit for the product class it covers: mere placement of such a label does not render a product exempt from requirements that would otherwise apply, because a product's intended use is determined from the objective intent of those responsible for labelling it, including the circumstances of distribution and how it is marketed. On the medicines side the same logic applies under the Federal Food, Drug, and Cosmetic Act, whose implementing regulation defines the intended use of a drug by reference to the objective intent of the persons legally responsible for its labelling, shown among other things by the circumstances surrounding its distribution. The regulatory status of a substance follows from what it is and how it is presented, not from a sentence printed on a carton. The status question itself is a separate topic, covered in are peptides legal.
Peptide vial labels after reconstitution
Once diluent has been added, the printed label is no longer complete: it describes a solid, and the container now holds a solution at a concentration that only exists because of what was added. Pharmacy practice solves this by relabelling, and it is the reason home-made peptide vial labels exist at all. USP General Chapter 797, Section 13 lists what the immediate container label of a compounded sterile preparation displays prominently and legibly: an identification number, the active ingredient and its amount or concentration, the storage condition where it differs from controlled room temperature, the beyond-use date, the dosage form, the total amount or volume, and a statement of whether the container is single-dose or multiple-dose.
Translated to a container in a drawer at home, that is five fields.
| Field | What it records | Example entry |
|---|---|---|
| Name | The identifier used everywhere else, so the container and the record refer to the same thing | Peptide A |
| Reconstitution date | The day diluent was added and the closure first punctured. This is the date the beyond-use clock runs from | D (the day diluent was added) |
| Quantity in the container | The labelled amount of solid, M mg | M mg |
| Diluent volume added, and the resulting concentration | V mL added to M mg gives M divided by V, in mg/mL | V mL, M/V mg/mL |
| Use-by date | The end of the beyond-use period that applies to the preparation, under the storage condition actually in use | D plus the beyond-use period stated for the specific product |
Where the storage condition differs from controlled room temperature, pharmacopoeial convention adds a line for it; a container living in a refrigerator says so on its label.
What is deliberately absent is a dose field, and also any field in insulin-syringe units or in millilitres per withdrawal. The reason is structural rather than legal. A unit number is only meaningful together with one particular syringe scale and one particular concentration, and the label stays with the container while syringes come and go, so a units figure written on glass outlives the very changes that make it wrong. Concentration mix-ups are a documented and growing category in poison-centre data, as the analysis of reported preparation errors sets out, and a label that carries mg, mL and the resulting mg/mL keeps the arithmetic reconstructable while a label carrying a single number does not. The conversion itself lives in mg, mL and IU, the step that produces the solution in reconstituting peptides, and the diluent question in bacteriostatic water and the bacteriostatic versus sterile water comparison.
The physical label has its own small constraints. Paper and adhesive behave differently at 2 to 8 degrees Celsius than at room temperature, condensation on cold glass lifts edges, and water-soluble ink runs when that condensation reaches it. A label wrapped around a curved 2R body also leaves very little flat area, which is one reason the field list is short. myPeptides keeps a vial register with the same minimum: the date a container was opened, its batch number and a name of its own.
How long a peptide vial lasts
The question has two answers because two independent processes are running, and whichever expires first is the one that counts.
| State | Governing clock | Convention | Source of the convention |
|---|---|---|---|
| Unopened, freeze-dried solid | Chemical stability | The expiry date on the container, under its labelled storage condition | Manufacturer's stability data; USP General Chapter 659 |
| Freeze-dried solid, container closed, in storage | Chemical stability, driven by residual moisture, temperature and light | The labelled temperature class, as defined in USP General Chapter 659 | USP General Chapter 659 |
| Entered single-dose container, no preservative | Microbiological | Used up to 12 hours after initial puncture, in ISO Class 5 or cleaner air; an opened ampoule is not stored | USP General Chapter 797, Section 15.1 |
| Entered multiple-dose container, preserved | Microbiological | 28 days from first entry, unless the labelling specifies otherwise, and never beyond the expiry date | USP General Chapter 797, Section 15.2; FDA 2018; CDC |
| Reconstituted solution generally | Both, and the shorter one wins | Whatever the product's own labelling states. Where no such statement exists, no beyond-use period has been established | Pharmacopoeial and label practice |
The preservative is what makes the difference between the third and fourth rows. Bacteriostatic Water for Injection, USP, for instance, is described on its label as supplied in a multiple-dose container from which repeated withdrawals may be made, and it contains benzyl alcohol as a bacteriostatic preservative; unpreserved diluents carry no such statement. The package type terms and the 28-day convention above describe conventionally manufactured containers as labelled by their manufacturer; a preparation compounded outside that labelling takes its beyond-use period from the compounding standard that applies to it (USP General Chapter 797, Sections 13 and 14), not from the multiple-dose convention.
Two things this table does not do. It does not express duration as a number of withdrawals, because that depends on volume per withdrawal, which is outside the scope of this page. And it does not override anything: for an approved medicine, the beyond-use statement in that product's own labelling replaces every general convention listed here. Preparations that live in a syringe rather than a container follow different reasoning again, set out in storing peptides in syringes, and combining more than one solution introduces a separate failure mode described in mixing peptides in one syringe.
Common questions
Why is there almost no powder in my vial?
A few milligrams of solid spread across the base of a vial is close to invisible, and freeze-drying leaves that solid as a light, porous structure rather than a dense heap. Appearance carries no information about content: quantity is a matter of the manufacturing record and the label, not of what the eye can see.
How to store lyophilized peptides?
Freeze-dried peptide is kept in the container it was sealed in, at the temperature class its labelling states, protected from light and from moisture. The container is part of that arrangement rather than packaging around it: the closure was pressed home inside the dryer under vacuum or inert gas and the crimp cap holds it under permanent compression, which is what keeps the surrounding atmosphere out. Because a dried amorphous solid is hygroscopic, humidity is as much a variable as temperature, which is why an intact closure system and the original opaque packaging matter alongside the storage class.
Do lyophilized peptides need to be refrigerated?
Not as a general rule. Freeze-dried presentations exist because a dry solid tolerates ambient conditions that the same substance in water does not, and the storage statement printed on a container is a property of that particular formulation rather than of peptides as a class. Pharmacopoeial temperature classes run from freezer through refrigerated to controlled room temperature, and which one applies is stated on the label together with the expiry date that class supports. Where a container carries no such statement, no storage condition has been established for it.
How do you open a peptide vial?
A vial is not unsealed in the ordinary sense. The flip-off disc in the centre of the cap is a tamper-evident cover: lifting it exposes the elastomeric septum underneath, while the aluminium crimp ring around the flange stays in place, because it is the ring rather than the disc that holds the closure and keeps the container closed. Access runs through the septum, which reseals after a needle is withdrawn. USP General Chapter 797, Section 8.3 treats vial stoppers as critical sites, wiped with sterile 70% isopropyl alcohol and allowed to dry before entry.
What should a vial label say?
Pharmacopoeial labelling convention for a prepared container covers identity and strength, the storage condition where it differs from room temperature, a beyond-use date, the dosage form, the total amount or volume, and a statement of whether the container is single-dose or multiple-dose. USP General Chapter 797, Section 13 lists these elements for compounded sterile preparations; a dose is deliberately not among them.
How long does a peptide vial last?
Two separate clocks run. Unopened, the manufacturer's expiry date and the labelled storage condition govern. Once the closure has been punctured a microbiological clock starts: pharmacy convention gives a preserved multiple-dose container a beyond-use date of 28 days from first entry unless the manufacturer's labelling states otherwise, and an unpreserved single-dose container far less.
What is the vial designed for?
A vial is a closed container built to keep a sterile content sterile and chemically unchanged until it is withdrawn through the closure. FDA's package type terms distinguish single-dose containers, which need no antimicrobial preservative and are intended for one withdrawal, multiple-dose containers, which are preserved, generally hold 30 mL or less and allow repeated withdrawals, and single-patient-use containers.
Sources
- U.S. Food and Drug Administration, Selection of the Appropriate Package Type Terms and Recommendations for Labeling Injectable Medical Products Packaged in Multiple-Dose, Single-Dose, and Single-Patient-Use Containers for Human Use. Guidance for Industry, October 2018. https://www.fda.gov/media/117883/download
- USP General Chapter 797, Pharmaceutical Compounding, Sterile Preparations (Sections 8.3, 13, 15.1, 15.2). https://www.usp.org/compounding/general-chapter-797
- USP General Chapter 659, Packaging and Storage Requirements (temperature and storage definitions; expiration date and beyond-use date). Chapter text: https://doi.usp.org/USPNF/USPNF_M2773_06_01.html and Revision Bulletin: https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/revisions/659_rb_notice.pdf
- USP General Chapter 660, Containers, Glass. https://doi.usp.org/USPNF/USPNF_M1757_01_01.html
- ISO 8362-1:2018, Injection containers and accessories, Part 1: Injection vials made of glass tubing. Dimensional values (overflow capacity, outer diameter, height) quoted from Table 1 of that edition. https://www.iso.org/standard/74398.html
- ISO 8362-2, Injection containers and accessories, Part 2: Closures for injection vials. https://www.iso.org/standard/87251.html
- ISO 8362-3, Injection containers and accessories, Part 3: Aluminium caps for injection vials. https://www.iso.org/standard/33804.html
- ISO 8362-5, Injection containers and accessories, Part 5: Freeze drying closures for injection vials. https://www.iso.org/standard/33806.html
- ISO 8362-6, Injection containers and accessories, Part 6: Caps made of aluminium-plastics combinations for injection vials. https://www.iso.org/standard/33807.html
- ISO 8362-7, Injection containers and accessories, Part 7: Injection caps made of aluminium-plastics combinations without overlapping plastics part. https://www.iso.org/standard/33808.html
- U.S. Food and Drug Administration, Lyophilization of Parenteral (7/93), Inspection Guide. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/lyophilization-parenteral-793
- Patel SM, Nail SL, Pikal MJ, Geidobler R, Winter G, Hawe A, Davagnino J, Rambhatla Gupta S. Lyophilized Drug Product Cake Appearance: What Is Acceptable? Journal of Pharmaceutical Sciences, 2017;106(7):1706-1721. https://doi.org/10.1016/j.xphs.2017.03.014
- Wang W. Lyophilization and development of solid protein pharmaceuticals. International Journal of Pharmaceutics, 2000;203(1-2):1-60. https://doi.org/10.1016/S0378-5173(00)00423-3
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010;27(4):544-575. https://doi.org/10.1007/s11095-009-0045-6
- Centers for Disease Control and Prevention, Preventing Unsafe Injection Practices, last reviewed 26 March 2024. https://www.cdc.gov/injection-safety/hcp/clinical-safety/index.html
- Bacteriostatic Water for Injection, USP, prescribing information, DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87d6e9dc-fe3b-4593-ac9a-d7493d1959c7
- U.S. Food and Drug Administration, Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only. Guidance, November 2013. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/distribution-in-vitro-diagnostic-products-labeled-research-use-only-or-investigational-use-only
- 21 CFR 201.128, Meaning of intended uses (objective intent of the persons legally responsible for the labeling of drugs). https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-G/section-201.128
Everything above describes packaging standards, pharmacopoeial conventions and published stability chemistry. None of it displaces the labelling of a specific product: for an approved medicine, the storage statement, the beyond-use statement and the package type statement on that product's own label govern, and questions about a particular preparation belong with a licensed physician or pharmacist.